Doctors login


Croma-Pharma GmbH establishes affiliate in UK

Croma-Pharma has now terminated the cooperation with its former distributor Schuco by mutual agreement to build up its own sales structure.

Starting in September 2019, Croma will establish its own London-based affiliate to market its product portfolio in the field of minimally invasive aesthetic medicine in the UK. The cooperation with the previous distributor Schuco was terminated by mutual agreement. Croma is pleased to welcome Julian Popple as its new UK Country Manager who has launched a range of pharmaceutical and aesthetics products for large pharmaceutical companies in the UK, Germany and Italy. Together with his team, he will position and distribute Croma´s aesthetic portfolio. Besides the HA Filler from the own production site as the main product, Croma markets PDO lifting threads, a Platelet Rich Plasma (PRP) system in cooperation with Arthrex and the personalised skincare UniverskinTM in the UK. “Croma aims to provide the best product quality to its customers, while also supporting them to grow their business. An own affiliate office in the UK enables a much closer cooperation and stronger working relationship with our customers”, emphasises managing director Andreas Prinz. Furthermore, Croma will launch its new branded HA Filler saypha® at the CCR from 10 - 11/10/2019 on the UK market.

Croma-Pharma donates for blind people in Africa

The Lower Austrian pharmaceutical company Croma-Pharma supports the charitable organization Licht für die Welt by donating medical products (viscoelastics).

Last week, Croma-Pharma, represented by Martin Schöller (Managing Director), again presented a generous donation of medical products (viscoelastics) for the operation on cataracts to Licht für die Welt.

For 18 years, Croma-Pharma supports the organization's work with generous product donations that enables hundreds of thousands of eye surgeries. "Croma stands for the right of people in poverty areas to provide quality medical care. Therefore, we have been supporting the work of Licht für die Welt for many years pleased to be able to make a contribution to sustainably improving the quality of life of these people, "emphasized Martin Schöller. 

Cataract is still the leading cause of blindness in the world. This operation costs on average only 30 euros and takes about 15 minutes. A brief moment, however, which gives the affected people their eyesight for a lifetime.

Jung v. Matt/ Donau & Croma won CCA-Venus-Award in Bronze

The aesthetic pictures of the brand campaign could convince in the category photography.

This year Croma Pharma and the agency Jung von Matt/Donau won the bronze Venus Award in the field of photography with the subjects of the brand campaign.
The most important creative price of Austria honors the best ideas of the communication industry for the market place Austria and places their creators as well as their clients into the spotlight.

Fotocredit CCA/H.Plein/P.Lichtenegger

Croma launches newly registered PDO sutures for tissue elevation

Croma, short for CROMA-PHARMA GmbH, strives for innovation in order to maximize its customers’ and patients’ well-being. Therefore in May 2019 Croma proudly introduces threadz®– the outstanding newcomer in minimally invasive aesthetic medicine.

threadz® is one of the first PDO sutures for tissue elevation that has been registered according to the existing Medical Device Law. The safety and efficacy performance of the product has been verified during the successful conformity assessment procedure, allowing Croma to offer threadz® for minimally invasive tissue elevation. 

threadz® is the result of a long and comprehensive development process embracing science, knowledge, and expertise.

Croma is committed to high quality standards, thus threadz® are produced by a U.S. manufacturer with over 40 years of experience, trusted for its quality in development and production of surgical devices. Croma designed threadz® in close collaboration with experienced healthcare professionals and optimized the product according to their needs and requirements to increase efficacy and patients´ satisfaction.  Therefore the product includes unique, registered, gloves friendly, comfortable grip hub with ergonomic shape and specially coated thin-wall needle/cannula for better glide for smooth and easy application.

Healthcare professionals can discover convenience, simplicity, and the efficacy of the new product, which is available in 3 subtypes: 

  • threadz® plain – unmodified monofilament housed in needle  for delicate fixation of the thin skin in some areas (e.g. periorbital).
  • threadz® screw – spiral configuration of the suture housed in needle for better fixation in the tissues.
  • threadz® barbed – sutures with bi-directional helically 3D oriented barbs, housed either on needle or cannula for stronger repositioning effect.

To offer the optimal freedom of choice, these subtypes are available in different sizes. Doctors can choose the most appropriate suture for different anatomical zones and address individual patients’ needs in a best possible way.

Cromais proud of its wide portfolio of PDO sutures for minimally invasive skin elevation. Additionally to the newly released threadz® range, Cromastill offers its most popular product of Princess® Threads line: Princess® Threads Barb II Anchor – with “cold pressed & sculptured” arrow shaped cogs for ultimate elevation effect.

Croma-Pharma completes rebranding of its HA filler range

On January 02nd, Croma-Pharma GmbH (Croma) has stated that the company is moving forward in its plan harmonizing the different brands of its aesthetic product portfolio.

 The previous HA filler brand “Princess®” is replaced by the brand “saypha®” in a gradual process throughout international markets, focusing on Europe in the first place.

First and foremost the rebranding became necessary due to Croma’s ongoing globalisation process on the one hand and the advancing approval procedures of  Hugel’s botulinum toxin product Botulax on the other hand, requiring a more medical HA filler brand, exclusively addressing medical professionals. Croma has licensed the product Botulax from the Korean toxin producer Hugel Inc. for Europe and recently established a joint venture company with Hugel, Inc., in order to develop and commercialize Croma’s HA filler and PDO thread products together with Hugel’s product Botulax in the US, Canada, Australia and New Zealand.

Croma’s Managing Director, Andreas Prinz, further explained, “By replacing Princess® with saypha® we actually pursue several different purposes. Primarily, Princess® is not a suitable and approvable brand for all our current and future markets. Furthermore the saypha® brand is consistent with Croma as the all-encompassing umbrella brand, introduced in 2017, under which every product can be streamlined and marketed with a unifying look and feel around the globe. 
In the course of our progressing internationalization process this standardized appearance of the company towards our primary target audience, the medical professionals, becomes absolutely essential. Apart from that, all saypha® products are easy to distinguish from each other which was a customers’ request that we are happy to follow herewith. The saypha® brand also reflects medical science and evidence based medicine, values that Croma felt committed to at any time. In short, by introducing saypha® we are creating a strong global HA filler brand that stands for comprehensive quality, reliability and medical effectiveness.”


About saypha®

The Croma HA filler range consists of six products: saypha® RICH, saypha® FILLER (with/without lidocaine), saypha® VOLUME (with/without lidocaine) and saypha® VOLUME PLUS Lidocaine.

Innovation Award for Croma-Pharma

Croma wins German Innovation Award for Lacrimera®

Leobendorf, Juli  2018–As part of the German Innovation Award 2018, Croma received the Winner award for Lacrimera® eye drops in the Medical & Health category. Lacrimera® eye drops are characterised by a multi-patented mode of action that allows a 24-hour ocular surface retention time and to a sustainable treatment of dry eye symptoms. The protective layer created by Lacrimera® eye drops promotes the regeneration of the corneal surface.The prize, awarded in the "Excellence in Business to Consumer" competition class, distinguishes products and solutions across all sectors, which are differentiated above all by user-centeredness and added value compared to previous solutions.

The German Innovation Award is awarded by the German Design Council, which was established by the German Bundestag and endowed by German industry. Only companies nominated by the Expert Committees and Scouts of the German Design Council can participate. The jury is composed of independent, interdisciplinary experts from industry, science, institutions and finance.

Croma is a global player in the dynamically growing segment of minimally invasive aesthetic medicine and a leading European processor of hyaluronic acid. The company sells an annual production of six million hyaluronic acid syringes and its growing aesthetic portfoliothrough a network of own sales organizations, strategic partnerships and distributors in nearly 80 countries. The family-owned company employs more than 350 people worldwide. Production takes place exclusively at the company headquarters in Leobendorf near Vienna, Austria.



Mag. Stefanie Höhn
Corporate Director Communications
Cromazeile 2
A-2100 Leobendorf
Tel.:     +43 676 846868 190


New global brand campaign by Croma

In the course of rolling out its new Corporate Design, Croma introduces a new look and feel for the B2B communication of the umbrella brand CROMA. This international campaign primarily supports the image building of the brand CROMA as a strong, quality-conscious and medical partner of our customers.

In communication with our customers — the medical professionals — we now also rely on a pictorial language that artistically underscores the medical-clean logo image, providing Croma with a face and telling a story to the market.

We celebrate beauty with the imagery of our Global Brand campaign. The campaign will unfold its full force by interaction of the uniqueness of the motives with slightly irritating elements, which stands in contrast to the beauty of the protagonists.

Croma-Pharma GmbH sets the course for entering the US market

Croma-Pharma GmbH (Croma) is establishing a joint venture company with its long-time partner Hugel, Inc. to develop and commercialize botulinum toxin, HA filler and PDO thread products in US, Canada, Australia and New Zealand

On Sept 05th, Croma has stated that the company is moving forward in its plan preparing a successful launch of itsHA filler and PDO thread products on the US market. 

The joint venture company will be established with Croma’s Korean partner Hugel, Inc. Croma will be transferring its Botulax (Hugel´s botulinum toxin product) distribution rights for US, Canada, Australia, New Zealand, and also the 100% shares of its Canada and Australia subsidiaries in exchange for 30% of the joint venture company. Hugel will invest $90,000,000 in cash and future commitments and subscribe for equity representing 70% of the joint venture company. As a result of this transaction, the joint venture company will secure perpetual license to Croma’s HA filler and PDO thread products and Hugel’s botulinum toxin product in the aforementioned territories.  

Said joint venture company will be in charge of developing and commercializing Croma’s HA filler and PDO thread products and Hugel’s Botulax product in the US, Canada, Australia and New Zealand, and spearheading all clinical, regulatory, and marketing operations in order to ensure successful entry of the above products in the territories. Additionally, the joint venture company will be collaborating with Croma for marketing activities in Europe for a successful launch. 

Croma’s Managing Director, Andreas Prinz, explained, “By partnering with Hugel in these major aesthetic markets, we clear another hurdle in our international expansion process, while intensifying our relationship with Hugel. Both companies will certainly benefit from the experiences we make together in North America and Australia. Croma and Hugel will be moving closer together, based on mutual respect and trust.”

Hugel’s CEO, Jihoon Sohn, stated, “US is a huge market that currently accounts for the majority of the global botulinum toxin market.” He also added, “We have taken the very first step of our global initiatives, and through it, we plan to further strengthen our global footprint with our long-term partner, Croma.” 

About Croma-Pharma GmbH

Founded in 1976, Croma-Pharma GmbH (Croma) is an Austrian family-owned company that specializes in the industrial production of hyaluronic acid syringes for the fields of medical aesthetics, ophthalmology and orthopaedics. Croma currently runs 12 international sales companies and distributes its products in more than 70 countries. Within its global sales network, Croma focuses with own branded products on minimally invasive aesthetic medicine. Besides a broad range of HA Fillers from the own production site, Croma markets PDO lifting threads, a Platelet Rich Plasma (PRP) system and a personalized skincare technology in its core strategic markets.

About Hugel, Inc.

Hugel is a biopharmaceutical company developing and manufacturing botulinum toxin and HA filler products for use in not only medical aesthetic field, but also in medical therapeutic field. Hugel’s botulinum toxin product, Botulax, is currently marketed in 26 countries worldwide. In addition, Botulax is expected to enter the world’s largest markets such as US, Europe, and China soon. The Chaeum (Dermalax), Hugel’s HA filler product, is currently exported to 14 countries and is expecting approvals in 6 additional countries, including China, Brazil, and Chile.


Mag. Stefanie Höhn
Corporate Director Communications
Cromazeile 2
A-2100 Leobendorf
Phone .: +43 676 846868 190


~ ~